Novel Strategies in the Design and Production of Vaccines

1. Front Matter

   Pages i-xv

   PDF

2. Recombinant Antigens and Presentation Vectors

   1. Synthetic Vaccines for Infectious and Autoimmune Diseases

      • Michael Sela

      Pages 1-5

   2. Host Range Restricted, Non-Replicating Vaccinia Virus Vectors as Vaccine Candidates

      • Bernard Moss, Miles W. Carroll, Linda S. Wyatt, Jack R. Bennink, Vanessa M. Hirsch, Simoy Goldstein et al.

      Pages 7-13

   3. Hybrid Hepatitis B Virus Core Antigen as a Vaccine Carrier Moiety

      • F. Schödel, S. Kelly, S. Tinge, S. Hopkins, D. Peterson, D. Milich et al.

      Pages 15-21

   4. Synthetic Recombinant Vaccine Induces Anti-Influenza Long-Term Immunity and Cross-Strain Protection

      • Ruth Arnon, Raphael Levi

      Pages 23-29

   5. Alphavirus-Based Expression Systems

      • Charles M. Rice

      Pages 31-40

   6. Alphavirus Hybrid Virion Vaccines

      • A. Shafferman, S. Lustig, Y. Inbar, M. Halevy, P. Schneider, T. Bino et al.

      Pages 41-47

   7. DNA Vaccines for Bacteria and Viruses

      • J. B. Ulmer, R. R. Deck, A. Yawman, A. Friedman, C. Dewitt, D. Martinez et al.

      Pages 49-53

3. Bacterial Vaccines - Novel Approaches

   1. New Vaccines Against Bacterial Toxins

      • Rino Rappuoli, Mariagrazia Pizza, Gill Douce, Gordon Dougan

      Pages 55-60

   2. Parameters for the Rational Design of Genetic Toxoid Vaccines

      • W. Neal Burnette

      Pages 61-67

   3. Protective Immunity Induced by Bacillus anthracis Toxin Mutant Strains

      • C. Pezard, J.-C. Sirard, M. Mock

      Pages 69-72

   4. Bacterial Outer Membrane Protein Vaccines

      • Jan T. Poolman

      Pages 73-77

4. Strategies for HIV Vaccine

   1. Changing Paradigms for an HIV Vaccine

      • Alan M. Schultz

      Pages 79-90

   2. Complexed HIV Envelope as a Target for an AIDS Vaccine

      • J. M. Gershoni, G. F. Denisova, D. Raviv, B. Stern, J. Zwickel

      Pages 91-96

   3. HIV—Peplotion Vaccine

      • Yechiel Becker

      Pages 97-104

5. Adjuvants and Delivery Systems

   1. The Role of Adjuvants and Delivery Systems in Modulation of Immune Response to Vaccines

      • Rajesh K. Gupta, Paul Griffin Jr., An-Cheng Chang, Rachel Rivera, Roger Anderson, Bradford Rost et al.

      Pages 105-113

   2. Unique Immunomodulating Properties of Dimethyl Dioctadecyl Ammonium Bromide (DDA) in Experimental Viral Vaccines

      • D. Katz, S. Lehrer, O. Galan, B. Lachmi, S. Cohen, I. Inbar et al.

      Pages 115-125

6. Production Processes and Clinical Evaluation

   1. Challenges in the Development of Combination Vaccines

      • Ronald W. Ellis

      Pages 127-132

   2. Polysaccharide Conjugate Vaccines for the Prevention of Gram-Positive Bacterial Infections

      • Robert Naso, Ali Fattom

      Pages 133-140

   3. Production of Influenza Virus in Cell Cultures for Vaccine Preparation

      • O.-W. Merten, C. Hannoun, J.-C. Manuguerra, F. Ventre, S. Petres

      Pages 141-151

Vaccination is one of the most efficient and cost effective methods of promoting human health and has been in clinical use for at least 200 years. Nevertheless, infectious diseases continue to constitute a constant threat to the well being of humanity. Common pathogens, once believed to be under control, acquire increased virulence and resistance to drugs, while exotic microorganisms emerged from hidden reservoirs to cause yet incurable diseases in humans. These changes, together with epidemic outbreaks related to political and socio-economic instabilities, increase the needs for the development of new, advanced vaccines. In this volume, devoted to the proceedings of the 39th OHOLO Conference, we present some of the recent strategies for the design and production of novel vaccines. The advent of recombinant DNA technology has stimulated the production of several subunit vaccines. In spite of the obvious advantages to this approach, the limited immuno­ genicity of many subunit candidates has hindered their development. Strategies to enhance the immunogenicity of subunit vaccines is therefore critical. Several approaches toward this goal, including design of novel adjuvants and delivery systems as well as design of advantageous carriers, are presented here. Among the carriers evaluated here are polypep­ tides (flagellin, HBV core antigen, J3-galactosidase), attenuated virions (Vaccinia, Sindbis), and nonpathogenic licensed bacteria (Salmonella).

• AIDS
• HIV
• antigen
• autoimmune disease
• bacteria
• bacterial infection
• bacterial infections
• infection
• infections
• infectious
• vaccine
• virus
• infectious diseases

• Israel Institute for Biological Research, Ness-Ziona, Israel

  Sara Cohen, Avigdor Shafferman

Policies and ethics